Journal of the American Academy of Child & Adolescent Psychiatry
SPECIAL ARTICLETreatment for Adolescents With Depression Study (TADS): Rationale, Design, and Methods
Section snippets
RATIONALE
At the time TADS was initiated in 1998, existing empirical literature supported the short‐term efficacy for both psychosocial and pharmacological interventions for adolescents with MDD. Developments since that time have expanded and consolidated this literature, especially for medication management, without substantively altering the rationale for TADS.
Cognitive‐behavioral therapy (CBT) as a treatment for MDD in youth has obtained strong empirical support for close to two decades (Harrington et
SPECIFIC AIMS AND DESIGN
The specific research objectives were clearly spelled out by the National Institute of Mental Health (NIMH) in the RFP:
Using a sufficiently large sample of patients representative of those found in clinical practice, (a) What is the long‐term effectiveness of pharmacological treatment of adolescents with major depression? What is the impact of treatment on symptom reduction, disorder remission, and level of functioning in school, at home, or in the community, and on the use of auxiliary
PRIMARY OUTCOME MEASURES
Two well‐validated primary outcome measures—one scalar and one categorical—as rated by an independent evaluator were selected: (1) the Children's Depression Rating Scale‐Revised total score based on the synthesis of information collected from interviewing both the adolescent and the parent (Poznanski and Mokros, 1995); and (2) responder status (dichotomized at much improved or better) on the Clinical Global Impressions‐Improvement (CGI‐I) scale (Guy, 1976). Secondary outcome measures (as
SAMPLE SIZE AND POWER ESTIMATES
The primary endpoint used in the sample size estimate was treatment response rate at the end of stage I, which, based on convention and existing literature, was defined as a CGI‐I score of 1 or 2 (very much or much improved, respectively) assigned by the independent evaluator. Using a χ2 statistic, power estimates for detecting differences in treatment response in the four groups were then computed with the following assumptions: (1) Ha: P(FLX) = 0.60, P(CBT) = 0.60, P(COMB) = 0.80, and P(PBO)
SAMPLING FRAME AND SUBJECT RECRUITMENT
TADS will recruit a volunteer sample of 432 youth aged 12‐17 years (inclusive) with a primary DSM‐IV diagnosis of MDD. The most important inclusion and exclusion criteria are presented in TABLE 3, TABLE 4, respectively. Potential patients who refuse consent or fail eligibility requirements are offered clinically appropriate open treatment outside the study. Records are kept to allow comparison of those entering and not entering the study for purposes of assessing sample representativeness and
Overview
TADS treatments are designed according to “best practice” standards to allow ready dissemination (if warranted) into clinical practice at the conclusion of the trial. Using flexible dosing in the medication condition and a mix of required and modular session topics in CBT plus strategies for maintaining treatment gains, TADS treatments are carefully designed to maximize benefits and to minimize adverse events and patient noncompliance. Adjunctive Services and Attrition Prevention (ASAP)
PATIENT SAFETY AND ASAP
To ensure patient safety, evaluate the tolerability of treatment, and minimize the potential for cross‐site differences in protocol delivery, TADS provides integrated procedures for adverse event (AE) monitoring and ASAP, including manual‐based procedures for monitoring and responding to (1) worsening MDD, (2) adverse events, (3) concomitant medications, and (4) adjunctive services in response to, for example, emerging suicidality.
With respect to adverse event monitoring, TADS stays carefully
ASSESSMENTS
Following recommendations outlined by Burns and by Jensen and their colleagues (Burns, 1996; Jensen et al., 1996), the TADS assessment battery was crafted to provide information regarding the impact of treatment across multiple domains and informants.
As noted earlier, the two primary outcome measures targeting the symptoms of MDD as rated by an independent evaluator are (1) a clinical summary score on the Children's Depression Rating Scale‐Revised and (2) a dichotomized CGI‐I score. Secondary
QUALITY ASSURANCE
To ensure that all sites conduct the protocol in the same manner, quality assurance (QA) procedures covering administration of treatment and assessment protocols are critical to the success of a large, complex, multicenter trial such as TADS (Meinert, 1986). In particular, QA procedures are necessary to guarantee (1) consistent standardized administration of TADS treatments and (2) reliability of assessments defined as consistent standardized ascertainment of the study entry diagnosis and the
ORGANIZATION
TADS is funded by the NIMH as a contract to the Coordinating Center at Duke University Medical Center, with collaborating Program staff at the NIMH, statistical and other consultants, and collaborating scientists at 12 study centers. Under the direction of the Principal Investigator, John March, M.D., M.P.H., the Statistical Principal Investigator, Susan Silva, Ph.D., and the TADS Project Leader, Steven Petrycki, R.N., the Duke Clinical Research Institute provides overall leadership for the
STUDY TIMELINE
Year 1 (1999) was devoted to protocol development, recruiting and training sites, and piloting the CBT and medication protocol and assessment procedures in the above‐mentioned TADS feasibility study. It is expected that subject recruitment for the full trial will be completed in the spring of 2003 and all active treatment by the middle of year 6 of the award period. Stage IV follow‐up will be completed in the middle of year 7. Per the TADS Publication Guidelines, core paper(s) will be published
CONCLUSION
TADS stands at the confluence of current efforts to improve the treatment of adolescent depression and related outcomes. In a clinical context, TADS assessment and treatment protocols represent current “best practice” in the initial treatment of adolescents with MDD. Given links to related NIMH‐funded effectiveness studies, such as the Treatment of Resistant Depression in Adolescents (TORDIA) and the Treatment of Adolescent Suicide Attempters (TASA), TADS represents an important building block
REFERENCES (36)
- et al.
Emergency/adjunct services and attrition prevention for randomized clinical trials in children: the MTA manual-based solution
J Am Acad Child Adolesc Psychiatry
(2002) - et al.
Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders
J Am Acad Child Adolesc Psychiatry
(1998) - et al.
Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial
J Am Acad Child Adolesc Psychiatry
(2002) - et al.
Outcomes of mental health care for children and adolescents, II: literature review and application of a comprehensive model
J Am Acad Child Adolesc Psychiatry
(1996) - et al.
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial
J Am Acad Child Adolesc Psychiatry
(2001) - et al.
Major depression in community adolescents: age at onset, episode duration, and time to recurrence (see comments)
J Am Acad Child Adolesc Psychiatry
(1994) - et al.
Psychosocial treatments for adolescent depression
Clin Psychol Rev
(1999) - et al.
Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: a review and meta-analysis
J Am Acad Child Adolesc Psychiatry
(1998) - et al.
Depressive comorbidity in children and adolescents: empirical, theoretical, and methodological issues
Am J Psychiatry
(1993)
Perceived parental burden and service use for child and adolescent psychiatric disorders
Am J Public Health
Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder
Arch Gen Psychiatry
Cognitive Therapy Treatment Manual for Depressed and Suicidal Youth
Risk factors for adolescent suicide and suicidal behavior: mental and substance abuse disorders, family environmental factors, and life stress
Suicide Life Threat Behav
A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy
Arch Gen Psychiatry
The impact of adolescent suicide on siblings and parents: a longitudinal follow-up
Suicide Life Threat Behav
What drives outcomes for emotional and behavioral disorders in children and adolescents?
New Dir Ment Health Serv
Instructor's Manual for the Adolescent Coping with Depression Course
Cited by (162)
Double trouble: Do symptom severity and duration interact to predicting treatment outcomes in adolescent depression?
2020, Behaviour Research and TherapyPsychoeducation for exposure therapy
2020, Exposure Therapy for Children with Anxiety and OCD: Clinician's Guide to Integrated TreatmentEstimating patient-specific treatment advantages in the ‘Treatment for Adolescents with Depression Study’
2019, Journal of Psychiatric ResearchCitation Excerpt :Accordingly, it featured a relatively large sample that was quite heterogeneous, mirroring the heterogeneity of patients seen in actual clinical practice (Hollon et al., 2005; March et al., 2004; TADS Team, 2005). As such, its data was believed ripe for effect-modification analysis (TADS Team, 2003, 2005), and it was suggested that the TADS results should be broadly applicable to youths seeking treatment for depression across the USA (Hollon et al., 2005; March et al., 2004; TADS Team, 2005). The model-based random forest's ability to investigate patient heterogeneity comprehensively is clearly appropriate for such a sample.
Trajectories of Symptom Change in the Treatment for Adolescents With Depression Study
2019, Journal of the American Academy of Child and Adolescent PsychiatryCitation Excerpt :Complete descriptions of the TADS aims, rationale, and design have been published elsewhere.21
Treating a broader range of depressed adolescents with combined therapy
2018, Journal of Affective Disorders
The TADS is supported by NIMH contract N01MH80008 to Duke University (Principal Investigator: John March, M.D.). Fluoxetine and matching placebo are provided to TADS by an unrestricted education grant from Eli Lilly and Company to Duke University.
Article Plus (online only) materials for this article appear on the Journal's Web site: www.jaacap.com.